Alunbrig

Chemical Namebrigatinib
Dosage FormTablet (oral; 30 mg, 90 mg, 180 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyTakeda Pharmaceutical Company Limited
Approval Year2017

Indication

  • For the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
Last updated on 11/11/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Alunbrig (Brigatinib) Prescribing Information 2020Takeda Pharmaceutical Company Limited, Cambridge, MA
Document TitleYearSource
SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018). 2018Clinical and Translational Oncology
NCCN guidelines insights: Non–small cell lung cancer, version 5.2018.2018Journal of the National Comprehensive Cancer Network